A systematic review demonstrates that participants using retatrutide reported a higher incidence of nausea, decreased appetite, constipation, diarrhea, and vomiting
Evening or morning dosing does not prevent or worsen GI adaptationyour body's adjustment timeline remains constant
Neither is a substitute for real medical evaluation of persistent fatigue
Clinical data says yes, they do
Severe nausea, vomiting, and dizziness are less commonly reported with sublingual formulations, though they can still occur, especially at higher doses or when escalating too quickly
PlexusDx tirzepatide injections use standard 31-gauge needles optimized for clinical efficacy and patient tolerability, but consultations with PlexusDx providers can address individual preferences or concerns about injection technique